ANTARES PHARMA ANNOUNCES LICENSING AGREEMENT WITH TEVA FOR NOVEL INJECTOR DEVICE; EXCLUSIVE SUPPLY AND DEVELOPMENT AGREEMENT

Antares Pharma, Inc., announced having signed an agreement with Teva Pharmaceutical Industries Ltd. for the development and supply of a new Antares disposable injection device. Under the terms of the exclusive agreement, Teva is obligated to purchase all of its delivery device requirements from Antares for use with an undisclosed product that is subject to approval by regulatory authorities. The finished product is expected to be marketed in the United States and Canada. BIOWIRE (http://www.genengnews.com/news/bnitem.aspx?name=3381603)